These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges. Sachpekidis C; Alberts I; Rominger A; Afshar-Oromieh A Immunotherapy; 2019 Oct; 11(15):1267-1271. PubMed ID: 31496329 [No Abstract] [Full Text] [Related]
8. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Kratochwil C; Giesel FL; Eder M; Afshar-Oromieh A; Benešová M; Mier W; Kopka K; Haberkorn U Eur J Nucl Med Mol Imaging; 2015 May; 42(6):987-8. PubMed ID: 25573634 [No Abstract] [Full Text] [Related]
9. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
10. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917 [TBL] [Abstract][Full Text] [Related]
15. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):352-360. PubMed ID: 28440324 [TBL] [Abstract][Full Text] [Related]
16. EANM procedure guidelines for radionuclide therapy with Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799 [TBL] [Abstract][Full Text] [Related]
17. Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses. Al-Rashdan R; Al-Abdallat H; Sathekge MM; Mirzaei S; Shahait M; Al-Khawaldeh K; Abdlkadir AS; Lee S; Al-Ibraheem A Nuklearmedizin; 2024 Jun; 63(3):188-198. PubMed ID: 38262473 [TBL] [Abstract][Full Text] [Related]
18. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Ahmadzadehfar H; Essler M J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975 [No Abstract] [Full Text] [Related]
19. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735 [TBL] [Abstract][Full Text] [Related]
20. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile. Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C Molecules; 2020 May; 25(11):. PubMed ID: 32486054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]